Alnylam to Host Fourth Annual “RNAi Roundtable” Webcast Series
July 27 2017 - 8:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi
therapeutics company, today announced that it plans to host its 4th
annual series of “RNAi Roundtable” webcasts this summer and early
fall. The 2017 series will offer a range of presentations from
Alnylam scientists, clinical collaborators, and patients or patient
advocates, who will review recent progress in many of the Company’s
late-stage pipeline programs. In addition, one roundtable will
report the findings from the investigation into the ENDEAVOUR Phase
3 trial with revusiran. Each event will be webcast live on the
Investors page of the Company’s website, www.alnylam.com, and a
replay of the roundtables will be posted on the Alnylam website
approximately three hours after each event.
The 2017 RNAi Roundtable schedule will be as follows:
- Patisiran, in development for the
treatment of hereditary ATTR amyloidosisThursday, August 3,
10:30 am ET
- Revusiran investigation
resultsWednesday, August 9, 12:30 pm ET
- Platform advances in RNAi
therapeuticsWednesday, August 23, 3:30 pm ET
- Givosiran, in development for the
treatment of acute hepatic porphyriasThursday, September 7,
10:30 am ET
- Fitusiran, in development for the
treatment of hemophilia and rare bleeding disordersTuesday,
September 12, 10:30 am ET
About RNAi
RNAi (RNA interference) is a revolution in biology, representing
a breakthrough in understanding how genes are turned on and off in
cells, and a completely new approach to drug discovery and
development. Its discovery has been heralded as "a major scientific
breakthrough that happens once every decade or so," and represents
one of the most promising and rapidly advancing frontiers in
biology and drug discovery today which was awarded the 2006 Nobel
Prize for Physiology or Medicine. RNAi is a natural process of gene
silencing that occurs in organisms ranging from plants to mammals.
By harnessing the natural biological process of RNAi occurring in
our cells, the creation of a major new class of medicines, known as
RNAi therapeutics, is on the horizon. Small interfering RNA
(siRNA), the molecules that mediate RNAi and comprise Alnylam's
RNAi therapeutic platform, target the cause of diseases by potently
silencing specific mRNAs, thereby preventing disease-causing
proteins from being made. RNAi therapeutics have the potential to
treat disease and help patients in a fundamentally new way.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of patients who have
limited or inadequate treatment options. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
debilitating diseases. Founded in 2002, Alnylam is delivering on a
bold vision to turn scientific possibility into reality, with a
robust discovery platform and deep pipeline of investigational
medicines, including three product candidates that are in
late-stage development or will be in 2017. Looking forward, Alnylam
will continue to execute on its "Alnylam 2020" strategy of building
a multi-product, commercial-stage biopharmaceutical company with a
sustainable pipeline of RNAi-based medicines. For more information
about our people, science and pipeline, please visit
www.alnylam.com and engage with us on Twitter at @Alnylam.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170727005475/en/
Alnylam Pharmaceuticals, Inc.Investors and
Media:Christine Regan Lindenboom, 617-682-4340orInvestors:Josh
Brodsky, 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024